Ginsenoside-Rb1 targets chemotherapy-resistant ovarian cancer stem cells via simultaneous inhibition of Wnt/β-catenin signaling and epithelial-to-mesenchymal transition

Shan Deng, Chris Kong Chu Wong, Hung Cheng Lai, Alice Sze Tsai Wong

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Chemoresistance is a major clinical problem compromising the successful treatment of cancer. One exciting approach is the eradication of cancer stem/tumorinitiating cells (jointly CSCs), which account for tumor initiation, progression, and drug resistance. Here we show for the first time, with mechanism-based evidence, that ginsenoside-Rb1, a natural saponin isolated from the rhizome of Panax quinquefolius and notoginseng, exhibits potent cytotoxicity on CSCs. Rb1 and its metabolite compound K could effectively suppress CSC self-renewal without regrowth. Rb1 and compound K treatment also sensitized the CSCs to clinically relevant doses of cisplatin and paclitaxel. These effects were associated with the Wnt/β-catenin signaling pathway by downregulating β-catenin/T-cell factor-dependent transcription and expression of its target genes ATP-binding cassette G2 and P-glycoprotein. We also identified reversal of epithelial-to-mesenchymal transition as a new player in the Rb1 and compound K-mediated inhibition of CSCs. Rb1 and compound K treatment also inhibited the self-renewal of CSCs derived from ovarian carcinoma patients as well as in xenograft tumor model. Moreover, we did not observe toxicity in response to doses of Rb1 and compound K that produced an anti-CSC effect. Therefore, Rb1 should be explored further as a promising nutraceutical prototype of treating refractory tumors.

Original languageEnglish
Pages (from-to)25897-25914
Number of pages18
JournalOncotarget
Volume8
Issue number16
DOIs
Publication statusPublished - 2017

Fingerprint

Catenins
Epithelial-Mesenchymal Transition
Neoplastic Stem Cells
Ovarian Neoplasms
Drug Therapy
Neoplasms
Panax notoginseng
TCF Transcription Factors
Rhizome
Wnt Signaling Pathway
Saponins
P-Glycoprotein
Dietary Supplements
Drug Resistance
Heterografts
Therapeutics
Down-Regulation
Adenosine Triphosphate
Carcinoma
ginsenoside Rb1

Keywords

  • Cancer stem cells
  • Chemoresistance
  • Ginsenoside
  • Ovarian cancer
  • Wnt/β-catenin signaling

ASJC Scopus subject areas

  • Oncology

Cite this

Ginsenoside-Rb1 targets chemotherapy-resistant ovarian cancer stem cells via simultaneous inhibition of Wnt/β-catenin signaling and epithelial-to-mesenchymal transition. / Deng, Shan; Wong, Chris Kong Chu; Lai, Hung Cheng; Wong, Alice Sze Tsai.

In: Oncotarget, Vol. 8, No. 16, 2017, p. 25897-25914.

Research output: Contribution to journalArticle

@article{4d50aa3bac214bf381b0f53451fc9bd0,
title = "Ginsenoside-Rb1 targets chemotherapy-resistant ovarian cancer stem cells via simultaneous inhibition of Wnt/β-catenin signaling and epithelial-to-mesenchymal transition",
abstract = "Chemoresistance is a major clinical problem compromising the successful treatment of cancer. One exciting approach is the eradication of cancer stem/tumorinitiating cells (jointly CSCs), which account for tumor initiation, progression, and drug resistance. Here we show for the first time, with mechanism-based evidence, that ginsenoside-Rb1, a natural saponin isolated from the rhizome of Panax quinquefolius and notoginseng, exhibits potent cytotoxicity on CSCs. Rb1 and its metabolite compound K could effectively suppress CSC self-renewal without regrowth. Rb1 and compound K treatment also sensitized the CSCs to clinically relevant doses of cisplatin and paclitaxel. These effects were associated with the Wnt/β-catenin signaling pathway by downregulating β-catenin/T-cell factor-dependent transcription and expression of its target genes ATP-binding cassette G2 and P-glycoprotein. We also identified reversal of epithelial-to-mesenchymal transition as a new player in the Rb1 and compound K-mediated inhibition of CSCs. Rb1 and compound K treatment also inhibited the self-renewal of CSCs derived from ovarian carcinoma patients as well as in xenograft tumor model. Moreover, we did not observe toxicity in response to doses of Rb1 and compound K that produced an anti-CSC effect. Therefore, Rb1 should be explored further as a promising nutraceutical prototype of treating refractory tumors.",
keywords = "Cancer stem cells, Chemoresistance, Ginsenoside, Ovarian cancer, Wnt/β-catenin signaling",
author = "Shan Deng and Wong, {Chris Kong Chu} and Lai, {Hung Cheng} and Wong, {Alice Sze Tsai}",
year = "2017",
doi = "10.18632/oncotarget.13071",
language = "English",
volume = "8",
pages = "25897--25914",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "16",

}

TY - JOUR

T1 - Ginsenoside-Rb1 targets chemotherapy-resistant ovarian cancer stem cells via simultaneous inhibition of Wnt/β-catenin signaling and epithelial-to-mesenchymal transition

AU - Deng, Shan

AU - Wong, Chris Kong Chu

AU - Lai, Hung Cheng

AU - Wong, Alice Sze Tsai

PY - 2017

Y1 - 2017

N2 - Chemoresistance is a major clinical problem compromising the successful treatment of cancer. One exciting approach is the eradication of cancer stem/tumorinitiating cells (jointly CSCs), which account for tumor initiation, progression, and drug resistance. Here we show for the first time, with mechanism-based evidence, that ginsenoside-Rb1, a natural saponin isolated from the rhizome of Panax quinquefolius and notoginseng, exhibits potent cytotoxicity on CSCs. Rb1 and its metabolite compound K could effectively suppress CSC self-renewal without regrowth. Rb1 and compound K treatment also sensitized the CSCs to clinically relevant doses of cisplatin and paclitaxel. These effects were associated with the Wnt/β-catenin signaling pathway by downregulating β-catenin/T-cell factor-dependent transcription and expression of its target genes ATP-binding cassette G2 and P-glycoprotein. We also identified reversal of epithelial-to-mesenchymal transition as a new player in the Rb1 and compound K-mediated inhibition of CSCs. Rb1 and compound K treatment also inhibited the self-renewal of CSCs derived from ovarian carcinoma patients as well as in xenograft tumor model. Moreover, we did not observe toxicity in response to doses of Rb1 and compound K that produced an anti-CSC effect. Therefore, Rb1 should be explored further as a promising nutraceutical prototype of treating refractory tumors.

AB - Chemoresistance is a major clinical problem compromising the successful treatment of cancer. One exciting approach is the eradication of cancer stem/tumorinitiating cells (jointly CSCs), which account for tumor initiation, progression, and drug resistance. Here we show for the first time, with mechanism-based evidence, that ginsenoside-Rb1, a natural saponin isolated from the rhizome of Panax quinquefolius and notoginseng, exhibits potent cytotoxicity on CSCs. Rb1 and its metabolite compound K could effectively suppress CSC self-renewal without regrowth. Rb1 and compound K treatment also sensitized the CSCs to clinically relevant doses of cisplatin and paclitaxel. These effects were associated with the Wnt/β-catenin signaling pathway by downregulating β-catenin/T-cell factor-dependent transcription and expression of its target genes ATP-binding cassette G2 and P-glycoprotein. We also identified reversal of epithelial-to-mesenchymal transition as a new player in the Rb1 and compound K-mediated inhibition of CSCs. Rb1 and compound K treatment also inhibited the self-renewal of CSCs derived from ovarian carcinoma patients as well as in xenograft tumor model. Moreover, we did not observe toxicity in response to doses of Rb1 and compound K that produced an anti-CSC effect. Therefore, Rb1 should be explored further as a promising nutraceutical prototype of treating refractory tumors.

KW - Cancer stem cells

KW - Chemoresistance

KW - Ginsenoside

KW - Ovarian cancer

KW - Wnt/β-catenin signaling

UR - http://www.scopus.com/inward/record.url?scp=85017514403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017514403&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.13071

DO - 10.18632/oncotarget.13071

M3 - Article

AN - SCOPUS:85017514403

VL - 8

SP - 25897

EP - 25914

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 16

ER -